摘要
目的探讨阿霉素(ADM)持续静脉注射与静脉注射给药治疗恶性肿瘤的心脏毒性。方法恶性肿瘤患者102例,分为阿霉素持续静脉注射组(CIV组)51例。静脉注射组(BL组)51例,采用ADM50～60mg/m2,CIV组ADM持续静脉注射72～96h,BL组ADM经静脉注射30min,分别观察用药后的心脏毒性及疗效。结果在ADM累积剂量>300mg/m2时,CIV组和BL组的心电图改变率、CK-MB/CK值异常率、LVEF<55%发生率均存在显著性差异,BL组明显高于CIV组(P<0.05或P<0.01)。化疗2个周期后有效率无差异。结论ADM经持续静脉注射与静脉注射相比,持续静脉注射可减轻心脏毒性,且不影响治疗效果。
Objective To quest the cardiac toxicity of adriamycin （ADM） when administered by continuous intravenous and bolus infusion in malignant tumor. Methods 102 ease malignant tumor patients are divided into adriamyein continuous intravenous groups 51 case （ CIV group, n = 51 ） and bolus infusion 51 case （ BL group, n = 51 ） to receive 50 - 60 mg/m^2, adriamyein is continuous injected 72 - 96 hours in CIV group and 30-minute in BL group, observe cardiac toxicity and curative effect. Results when the cumulative close of ADM is over 300 mg/m^2, there are significant differences between CIV group and BL group in change rate of electrocardiogram and abnormal rate of ck-mb/ck and rate of left ventricular ejection fraction （LVEF） 〈 55%. Rate in BL group are more than in the CIV （ P 〈 0.05 or P 〈 0.01 ）. The curative respoue rate is not difference after 2 cycles chemotherapy. Conclusion Compared with ADM bolus infusion, ADM continuous intravenous can reduce the cardiac toxicity, and has no influ- ence on curative effect.
出处
《实用癌症杂志》
2009年第3期306-308,共3页
The Practical Journal of Cancer
关键词
阿霉素
持续静脉注射
静脉注射
心脏毒性
Adriamycin（ ADM ）
Continuous intravenous（CIV）
Bolus infusion（BL）
Cardiac toxicity
